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DFNA5 was first identified as a gene responsible for autosomal dominant deafness.
Different mutations were found, but they all resulted in exon 8 skipping during splicing
and premature termination of the protein. Later, it became clear that the protein also has
a tumor suppression function and that it can induce apoptosis. Epigenetic silencing of the
DFNA5 gene is associated with different types of cancers, including gastric and colorectal
cancers as well as breast tumors. We introduced the wild-type and mutant DFNA5 allele
in the yeast Saccharomyces cerevisiae. The expression of the wild-type protein was
well tolerated by the yeast cells, although the protein was subject of degradation and
often deposited in distinct foci when cells entered the diauxic shift. In contrast, cells had
problems to cope with mutant DFNA5 and despite an apparent compensatory reduction
in expression levels, the mutant protein still triggered a marked growth defect, which in
part can be ascribed to its interaction with mitochondria. Consistently, cells with mutant
DFNA5 displayed significantly increased levels of ROS and signs of programmed cell
death. The latter occurred independently of the yeast caspase, Mca1, but involved the
mitochondrial fission protein, Fis1, the voltage-dependent anion channel protein, Por1
and the mitochondrial adenine nucleotide translocators, Aac1 and Aac3. Recent data
proposed DFNA5 toxicity to be associated to a globular domain encoded by exon 2–6. We
confirmed these data by showing that expression of solely this domain confers a strong
growth phenotype. In addition, we identified a point mutant in this domain that completely
abrogated its cytotoxicity in yeast as well as human Human Embryonic Kidney 293T cells
(HEK293T). Combined, our data underscore that the yeast system offers a valuable tool to
further dissect the apoptotic properties of DFNA5.
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INTRODUCTION
Evasion of apoptosis is known to be an important factor in
tumorigenesis, but the underlying mechanisms are often not well
understood. Therefore, more research is required on the factors
that govern cellular decisions between malignant outgrowth or
programmed cell death, as this may eventually lead to the design
of more efficient anti-cancer therapies (Fulda and Debatin, 2004;
Bremer et al., 2006; Call et al., 2008). Here, we describe our find-
ings on the heterologous expression in yeast of a human protein
that has an important role in controlling the switch between cell
survival and cell death, i.e., DFNA5.
DFNA5 was originally identified in a Dutch family with auto-
somal dominant non-syndromic hearing impairment (Van Laer
et al., 1998). This association with hearing loss was later con-
firmed with the description of DFNA5 mutations in a Korean
family, two Chinese families and a second Dutch family (Yu
et al., 2003; Bischoff et al., 2004; Cheng et al., 2007; Park
et al., 2010). Although the mutations in these families are dif-
ferent, they all lead to exon 8 skipping during splicing, thereby
causing a frameshift and premature termination of the pro-
tein. Another type of mutation was reported in an Iranian
family, where an insertion of a cytosine at nucleotide posi-
tion 640 truncates the protein at a position corresponding to
exon 5 of the gene. However, this mutation does not segre-
gate with the hearing loss phenotype and is even present in
persons with normal hearing (Van Laer et al., 2007). Hence,
it appears that DFNA5-associated hearing loss is caused by a
gain-of-function mutation due to exon 8 skipping. To date,
the exact function of the DFNA5 protein is still unknown,
but recent evidence suggests that the protein harbors a pro-
apoptotic function (Op de Beeck et al., 2011a). Analysis of
the protein revealed that it consists of two globular domains
separated by a hinge region, whereby the first domain, consist-
ing of the amino acid residues 1–256, displays pro-apoptotic
activity, while the second domain, corresponding to residues
282–496, may serve as a regulator that shields the apoptosis-
inducing function of the first domain (Op de Beeck et al.,
2011b).
www.frontiersin.org July 2012 | Volume 2 | Article 77 | 1
Van Rossom et al. Yeast model for DFNA5 toxicity
Some studies also associated DFNA5 with several types of can-
cer, including gastric, colorectal as well as breast cancer. Emerging
evidence from the past years suggest that DFNA5 plays a role
as a tumor suppressor protein and that the corresponding gene
is epigenetically silenced through methylation (Thompson and
Weigel, 1998; Lage et al., 2001; Akino et al., 2007; Kim et al.,
2008a; Fujikane et al., 2010). Consistent with this role are the
observations that siRNA-mediated knock-down of DFNA5 in
non-malignant breast epithelial cell lines enhances colony num-
bers, colony size and cell growth (Kim et al., 2008b), while forced
expression ofDFNA5 in gastric cancer cell lines suppresses colony
formation (Akino et al., 2007). Also in support of a tumor sup-
pressor function are the reports that expression of the DFNA5
gene is controlled by p53 (Masuda et al., 2006) and that silencing
of the gene correlates with tumor cell resistance to chemothera-
peutic drugs (Lage et al., 2001).
Supported by the observation that the exon 8 splicing
mutant of DFNA5 (mutDFNA5), but not the wild-type allele
(wtDFNA5), triggers cell cycle arrest when expressed in the fission
yeast Schizosaccharomyces pombe (Gregan et al., 2003), we decided
to use yeast as a model to investigate the role of DFNA5 in more
detail. We expressed wtDFNA5 and mutDFNA5 in the budding
yeast Saccharomyces cerevisiae and analyzed the repercussions on
growth, oxidative stress, and the induction of programmed cell
death. Data obtained from the wild-type strain and a series of
deletion mutants confirmed that mutDFNA5 strongly induces
programmed cell death, a phenomenon being dependent on
mitochondrial integrity, but independent of the yeast caspase,
Mca1. In addition, the yeast model proved to be an ideal tool
to identify point mutants in the apoptosis-inducing domain of
DFNA5 that abrogated its ability to induce cytotoxicity.
MATERIALS AND METHODS
STRAINS, PLASMIDS, AND GROWTH ANALYSIS
In this study, we used the BY4741 wild-type strain (Brachmann
et al., 1998) and isogenic deletion strains of the genome-wide
collection (EUROSCARF, Frankfurt, Germany) lacking proteins
involved in programmed cell death as listed in Table 1. The
C-terminally HA-tagged full-length wtDFNA5 and mutDFNA5
cDNAs, the C-terminally EGFP fusion proteins and the wtDFNA5
first and second globular fragments were isolated and amplified
as previously described (Gregan et al., 2003; Op de Beeck et al.,
2011a,b) using the primers listed in Table 2. All amplified prod-
ucts were ligated into the pYX212 plasmid using either EcoRI
and BamHI or EcoRI and SalI restriction sites, thereby placing
the inserts under expression control of the constitutive TPI1 pro-
moter. The mutants HCA-F2R and HCA-A3R at the N-terminal
end of the first globular domain were generated by site directed
mutagenesis (Agilent, Santa Clara, CA, USA) in combinationwith
the custom designed primers listed in Table 2. All constructs were
verified by bidirectional sequencing on an ABI genetic analyser
3130xl (Applied Biosystems, Foster City, CA, USA). The con-
struction of the plasmid for Mito-RFP was previously described
(Westermann and Neupert, 2000). Standard transformation tech-
niques were applied (Gietz et al., 1992) and all strains were grown
at 30◦C in a selective minimal medium containing 2% of glucose
(SD-Ura). Growth profiles were determined in 96-well microtiter
Table 1 | Strain list.
Strain Genotype Reference/Source
BY 4741 Mata his31 leu20 Brachmann et al., 1998
met150 ura30
aac1 BY4741YMR056c::kanMX4 EUROSCARF
aac3 BY4741YBR085w ::kanMX4 EUROSCARF
aif1 BY4741YNR074c::kanMX4 EUROSCARF
dnm1 BY4741YLL001w ::kanMX4 EUROSCARF
fis1 BY4741YIL065c::kanMX4 EUROSCARF
mca1 BY4741YOR197w ::kanMX4 EUROSCARF
mdv1 BY4741YJL112w ::kanMX4 EUROSCARF
nma111 BY4741YNL123w ::kanMX4 EUROSCARF
nuc1 BY4741YJL208c::kanMX4 EUROSCARF
por1 BY4741YNL055c::kanMX4 EUROSCARF
por2 BY4741YIL114c::kanMX4 EUROSCARF
rny1 BY4741YPL123c::kanMX4 EUROSCARF
snl1 BY4741YIL016w ::kanMX4 EUROSCARF
tdh2 BY4741YJR009c::kanMX4 EUROSCARF
tdh3 BY4741YGR192c::kanMX4 EUROSCARF
tim18 BY4741YOR297c::kanMX4 EUROSCARF
ymr074c BY4741YMR074c::kanMX4 EUROSCARF
ysp1 BY4741YHR155w ::kanMX4 EUROSCARF
plates with continuous shaking at 30◦C in a Multiskan GO spec-
trophotometer (Thermo Fisher Scientific Inc., Waltham, MA,
USA). Overnight cultures of at least three different transformants
were diluted to start new cultures for growth analysis. Growth
was monitored until the stationary phase was reached. Growth
curves are depicted with scaled OD units and as the mean val-
ues of the transformants, with error bars representing standard
deviations. The growth profiles of the strains expressing HA- or
EGFP-tagged wtDNFNA5 or mutDFNA5 were compared to that
of a control strain transformed with either empty vector or a
plasmid allowing for expression of EGFP. The differences in time
required to reach half maximal optical densities (T1/2) were
calculated and used as standards for growth quantification. The
difference in T1/2 obtained for wtDFNA5 (T1/2 wtDFNA5-
Control) and mutDFNA5 (T1/2 mutDFNA5-Control) in the
BY4741 wild-type strain was used as reference and set as 100%.
Human Embryonic Kidney 293T cells (HEK293T) were sub-
cultured in 60mm dishes at a density of 2 × 106 cells in
Dulbecco’s modified Eagle’s medium containing 4500mg/l glu-
cose supplemented with 10% (v/v) fetal calf serum, 100U/ml
penicillin, 100μg/ml streptomycin and 2mM L-glutamine (all
products from Invitrogen, San Diego, CA, USA). The cells were
incubated overnight at 37◦C in a 5% CO2 humidified envi-
ronment. The plasmids used for wtDFNA5 and mutDFNA5
expression in mammalian HEK293T cells, after transfection with
lipofectamine, were described before (Op de Beeck et al., 2011b).
In addition, we used the pEGFP-N1 vector to construct plasmids
for the expression of HCA-F2R and HCA-A3R mutants.
WESTERN BLOT ANALYSIS
Yeast samples were grown in 3ml cultures on selective medium
and were harvested at an OD600 nm between 1.5 and 2.0. An equal
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Table 2 | Primer pairs.
Construct Forward primer Reverse primer
wtDFNA5-HA TATATATATAGAATTCATGTTTGCCAAAGCAACCAGGAATT GACCGGTGGATCCCGTGAATGTTCTCTGCCTAAAGC
mutDFNA5-HA TATATATATAGAATTCATGTTTGCCAAAGCAACCAGGAATT GACCGGTGGATCCCGAGGTTGGGTCTTCAAGATCAG
wtDFNA5-EGFP TATATATATAGAATTCATGTTTGCCAAAGCAACCAGGAATT TATATATAGTCGACGCTTGTACAGCTCGTCCATGCC
mutDFNA5-EGFP TATATATATAGAATTCATGTTTGCCAAAGCAACCAGGAATT TATATATAGTCGACGCTTGTACAGCTCGTCCATGCC
DFNA5 domain A TATATATATAGAATTCATGTTTGCCAAAGCAACCAGGAATT CGGTGGATCCCGGTCCAGGTAGACAGAGTCAAT
DFNA5 domain B AAGCTTCGAATTCTGGCCACCATGGACCCCCTGGTCTTTCGAGAG GACCGGTGGATCCCGTGAATGTTCTCTGCCTAAAGC
HCA-F2R mutant* GAGCTCAAGCTTCGAATTCTGATGCGTGCCAAAGCAACCAGG CCTGGTTGCTTTGGCACGCATCAGAATTCGAAGCTTGAGCTCG
HCA-A3R mutant* CGAGCTCAAGCTTCGAATTCTGATGTTTCGTAAAGCAACCAGG CCTGGTTGCTTTACGAAACATCAGAATTCGAAGCTTGAGCTCG
Restriction sites used for cloning are underlined.
*Site directed mutagenesis primers.
amount of cells were taken and lysed by boiling for 15min in SDS
sample buffer [50mM Tris (pH 8.0), 10mM β-mercaptoethanol,
2% SDS, 0.1% bromophenol blue, 10% glycerol]. Proteins were
separated by standard SDS-PAGE and blotted onto PVDF mem-
branes (Immobilon-P transfer membranes, Millipore, MA, USA).
For immunodetection we used the primary rabbit anti-HA or
anti-EGFP antibodies (Santa Cruz, CA, USA) and a secondary
horse radish peroxidase (HRP) conjugated goat anti-rabbit anti-
body (Santa Cruz, CA, USA). The endogenous yeast alcohol
dehydrogenase Adh2 served as internal standard. Membranes
were developed using the ECL detection kit (Thermo Scientific,
IL, USA).
FLOW CYTOMETRIC ANALYSIS OF CELL DEATH, ROS
ACCUMULATION AND CASPASE ACTIVITY
Tests for apoptotic and necrotic markers, using AnnexinV/
Propidium Iodide (AV/PI) co-staining, as well as ROS accumu-
lation, using the superoxide-driven conversion of non-fluorescent
dihydroethidium (DHE) to fluorescent ethidium, were performed
and quantified using BD Influx flow cytometry (BD Biosciences,
New Jersey, NJ, USA) as described previously (Büttner et al.,
2008). Yeast samples were harvested at different time points.
Samples were collected at mid-exponential phase at an OD600 nm
between 3.5 and 4.0, just after cells had traversed the diauxic
shift (PD) at an OD600 nm between 6.0 and 7.0, and in station-
ary phase (ST) at an OD600 nm of 8.5 or higher. Analysis of the
BD influx flow cytometry data was performed using the software
program FlowJo (Tree Star Inc., Ashland, MA, USA). Viability
tests of the HCA-F2R and HCA-A3R mutants in HEK293T cells
were performed on a FACScan flow cytometer (BD Biosciences,
New Jersey, NJ, USA) after staining of the cells with PI. Cell via-
bility was then determined as the ratio of cells showing no PI
fluorescence to the total cell population.
A previously described protocol was used to measure the cas-
pase activity (Madeo et al., 2002). Yeast cells grown on selective
medium were harvested at an OD600 nm of approximately 4.5.
A staining solution containing 10μM FITC-VAD-FMK in PBS
(CaspACE, Promega, WI, USA) was added to an amount of cells
corresponding to an OD600 nm of 0.5 and incubated for 20min at
room temperature. After washing and resuspension in 200μl PBS
flow cytometric analysis was performed using a 530/40 bandpass
filter.
FLUORESCENCE MICROSCOPY
Cells transformed with wtDFNA5 or mutDFNA5 fused to EGFP
were grown till mid-exponential or post-diauxic phase as indi-
cated and visualized using a Leica DM4000B fluorescence micro-
scope (Leica Microsystems GmbH, Wetzlar, Germany). Pictures
were taken with a Leica DFC420C camera using the Leica
Application Suite software. The percentages of post-diauxic cells
with or without inclusions were determined by manual counting
of at least 300 cells per sample.
Mitochondria were visualized by the expression of a
mitochondria-targeted red fluorescent protein, Mito-RFP
(Westermann and Neupert, 2000). To stain the vacuolar mem-
brane, cells were in the post-diauxic phase and incubated with
FM4-64 ([N-(3-triethylammoniumpropyl)-4-(p-diethylamino
phenylhexa-trienyl) pyridinium dibromide]; Molecular Probes,
Eugene, OR, USA) at room temperature for at least 30min
in a HEPES buffer containing 1% of glucose to facilitate the
uptake of FM4-64. To visualize the nucleus, we performed a
4’,6-diamidino-2-phenylindole (DAPI) staining. The cells were
harvested in the post-diauxic phase and incubated for 20min in
a phosphate buffer (0.04M K2HPO4, 0.01M KH2PO4, 0.15M
NaCl, 0.1 g/100ml NaN3) containing 50% ethanol. After washing
with PBS, DAPI was added (1μg/μl) and samples were incubated
at room temperature for 15min.
STATISTICAL ANALYSIS
All experiments included biological replicates and the use of inde-
pendent transformants. Statistical analysis was performed using
unpaired t-tests or One-Way ANOVA.
RESULTS
MUTANT DFNA5 INDUCES APOPTOTIC AND NECROTIC CELL
DEATH IN YEAST
To study the properties of human DFNA5 in a well-defined
model, we expressed the cDNAs of wtDFNA5 and mutDFNA5
in the BY4741 wild-type strain. We used high-copy-number
plasmids allowing expression of wtDFNA5 and mutDFNA5 as
C-terminally HA-tagged proteins under the control of the strong
constitutive TPI1 promoter. For wtDFNA5, this resulted in good
expression levels of the full-length protein, though we noticed
that the protein was subject of proteolytic degradation as evi-
denced by the presence of discrete breakdown products upon
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Western blot analysis (Figure 1A). A lower expression level was
obtained for mutDFNA5 and, interestingly, no major proteolytic
fragments were observed in this case, even not when higher con-
centrations of protein extracts were loaded or when the exposure
time of the immunoblots was increased. Growth analysis of the
transformants revealed that the expression of wtDFNA5 had only
amoderate effect on growth, while expression of mutDFNA5 trig-
gered a significant growth defect. The latter was characterized
by a longer doubling time and a lower maximal optical density
of the cultures (Figure 1B). Hence, as compared to a culture of
the BY4741 strain transformed with the empty plasmid, a culture
of cells expressing wtDFNA5 required on average only an addi-
tional 3 h (SD± 0.24) to reach half of the maximal optical density
(T1/2), whereas for a culture of cells expressing mutDFNA5
this T1/2 was extended to about 11.5 h (SD ± 0.32) (Table 3).
Combined these data suggest that yeast cells tolerated the pres-
ence of wtDFNA5 fairly well but have problems to cope with
mutDFNA5. Notably, since the mutant protein seemed to escape
the protein breakdown, the cells apparently counter selected and
reduced the expression of the mutant protein to prevent extreme
harmful effects.
It is known that cytotoxic effects instigated by heterologous
proteins are often a reflection of a failing protein quality con-
trol and clearance system, which then leads to enhanced oxidative
stress and eventually increased cell death [reviewed inWinderickx
et al., 2008]. To examine whether this is also the case for heterol-
ogous expression of DFNA5, we measured the level of reactive
oxygen species (ROS) using a DHE staining on culture samples
taken at different time points during growth (Figures 1C,D). In
mid-exponential cultures, the ROS levels were only significantly
increased in cells expressing mutDFNA5 when compared to the
control. However, once the cultures traversed the diauxic shift and
switched their metabolism to respiration, a marked increment of
the ROS level was observed for both the cells expressing wtDFNA5
and those expressing mutDFNA5. In case of wtDFNA5, the level
of ROS in the early post-diauxic phase was about three times
higher than that of the control cells and it further increased in
stationary phase. With mutDFNA5, the increment in ROS in the
early post-diauxic phase was comparable to wtDFNA5, though by
the time these cells reached the stationary phase the average ROS
level was lower than that of cells expressing wtDFNA5.
We also performed a co-staining with AV/PI to detect cells
showing signs of apoptotic and necrotic cell death (Figure 1E).
This again revealed that only the expression of mutDFNA5 sig-
nificantly enhanced cell death during the mid-exponential phase,
while both expression of wtDFNA5 or mutDFNA5 enhanced cell
death once the cultures were beyond the diauxic shift, albeit to a
different extent. More in particular, we noticed that in the post-
diauxic and stationary phase the expression of the wild-type and
especially the mutant allele triggered an increase in the num-
ber of late apoptotic (AV+/PI+) and necrotic cells (AV−/PI+)
and that in the stationary phase this was even associated with
a significant decrease in early apoptotic (AV+/PI−) cells. That
the increments of late apoptotic and necrotic cells are most pro-
nounced upon expression of mutDFNA5 is consistent with the
observed enhanced growth defect. Furthermore, these results
are also in agreement with previously reported observations of
enhanced apoptotic and necrotic cell death in mammalian cells
transfected with mutDFNA5 (Van Laer et al., 2004; Op de Beeck
et al., 2011b).
MUTANT DFNA5 ESCAPES PROTEIN QUALITY CONTROL
DEPOSITION AND INTERACTS WITH MITOCHONDRIA
To analyse the intracellular localization, we expressed wtDFNA5
and mutDFNA5 as a C-terminally tagged EGFP fusion. Their rel-
ative expression levels were comparable to those of the HA-tagged
counterparts. Furthermore, similar as for the HA-tagged ver-
sions, the wtDFNA5-EGFP fusion was subject to proteolytic
degradation, while this was by far less pronounced for the
mutDFNA5-EGFP fusion (Figure 1A). Despite of these similari-
ties, we noticed that the fusion proteins induced slightly enhanced
growth defects as judged from the T1/2 values calculated
based on the growth difference with control cultures express-
ing native EGFP (T1/2 wtDFNA5-EGFP: 4.60 h ± 1.27; T1/2
mutDFNA5-EGFP: 15.85 h ± 1.84; Table 3). Nonetheless, since
also in this case mutDFNA5-EGFP instigated a much higher cyto-
toxicity than wtDFNA5-EGFP, we reasoned that further analysis
would still provide important insight in the differential properties
of the proteins.
Fluorescence microscopy confirmed the difference in expres-
sion level between wtDFNA5-EGFP and mutDFNA5-EGFP. It
also showed that wtDFNA5-EGFP was evenly distributed over
the cytoplasm in mid-exponential growth phase, although we
noticed that about one fifth of the cells (22%) gradually accumu-
lated fluorescent material in more dense inclusions (Figure 2A).
This resulted in the formation of one or a few distinct deposits
by the time these cells reached the post-diauxic phase. Similar
as in transfected mammalian cells (Van Laer et al., 2004), the
distribution of mutDFNA5-EGFP in mid-exponential phase cells
appeared to bemore granulated and possibly confined to intracel-
lular structures, though it was difficult to assign a definite pattern
due to the low expression level of the fusion protein. In the post-
diauxic phase, inclusions were present in about one out of seven
cells that expressed mutDFNA5-EGFP (14%). As compared to the
deposits of wtDFNA5-EGFP, the inclusions formed by the mutant
protein were usually less intense and occurring as small foci in the
vicinity of the plasma membrane (Figure 2A).
It was previously shown that cells protect themselves by
sequestering breakdown products and damaged or aggregated
proteins in different protein quality control compartments,
referred to as aggresomes or JUNQ and IPOD. JUNQ repre-
sents a juxta-nuclear quality control compartment that serves as
a temporary storage site for misfolded proteins, keeping them
in an ubiquitinated, soluble state for either refolding or degra-
dation by the ubiquitin-proteasome system. IPOD, on the other
hand, is a perivacuolar compartment for the deposit of insol-
uble, non-ubiquitinated substrates, such as amyloidic proteins,
that possibly await clearance by means of autophagy (Bagola and
Sommer, 2008; Kaganovich et al., 2008). To analyse in more detail
the localization of the inclusions formed by wtDFNA5-EGFP and
mutDFNA5-EGFP, we performed stainings with DAPI and FM4-
64 to, respectively, visualize the nucleus and the vacuolar mem-
brane. This demonstrated that the larger deposits of wtDFNA5-
EGFP did not co-localize with the nucleus (Figure 2B). Instead,
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FIGURE 1 | Repercussions of wtDFNA5 and mutDFNA5 expression in
BY4741 wild-type cells. (A) Western blot analysis of protein extracts of the
BY4741 wild-type strain transformed with an empty plasmid (contr.) or
constructs allowing for the expression of C-terminally HA-tagged and
EGFP-tagged wtDFNA5 or mutDFNA5 as indicated. Immunodetection was
performed using primary antibodies directed against the HA-tag, EGFP, or
Adh2, which was used as loading control. The black arrow indicates
full-length wtDFNA5 and the gray arrow full-length mutDFNA5. The small
open arrowheads indicate a-specific bands detected by anti-EGFP. For
mutDFNA5, the lane marked with [oe] represents an overexposure of the
Western blot. (B) Growth of the BY4741 wild-type strain transformed with an
empty plasmid (light gray circles) or a construct allowing for expression of
C-terminally HA-tagged wtDFNA5 (dark gray squares) or mutDFNA5 (black
triangles). (C) Visualization of ROS producing cells in control cultures (contr.)
or cultures of cells expressing C-terminally HA-tagged wtDFNA5 or
mutDFNA5 in post-diauxic phase. (D) Quantification of ROS accumulation
using DHE staining in control cultures (contr.) or cultures of cells expressing
C-terminally HA-tagged wtDFNA5 or mutDFNA5 when sampled at the
mid-exponential growth phase (ME), at post-diauxic shift (PD), and in
stationary phase (ST). (E) Quantification of the number of AV/PI positive cells
in ME, PD, and ST phase of control cells or cells expressing HA-tagged
wtDFNA5 or mutDFNA5. Significances were assayed using unpaired t-tests.
For the AV/PI co-staining the following significances were obtained when
compared to the control: for wtDFNA5 in ME: AV−/PI+ *; for wtDFNA5 in PD:
AV+/PI+ ***, AV−/PI+ *; for wtDFNA5 in ST: AV+/PI− *, AV+/PI+ *, AV−/PI+
**; for mutDFNA5 in ME: AV+/PI− *, AV+/PI+ **, AV−/PI+ **; for mutDFNA5
in PD: AV+/PI− **, AV+/PI+ *, AV−/PI+ ***; for mutDFNA5 in ST AV+/PI−
**, AV+/PI+ **, AV−/PI+ *. (* = p < 0.05; ** = p < 0.01; *** = p < 0.001).
www.frontiersin.org July 2012 | Volume 2 | Article 77 | 5
Van Rossom et al. Yeast model for DFNA5 toxicity
Table 3 | Quantification of growth*.
Strain Function T1/2 Control T1/2 wtDFNA5 T1/2 mutDFNA5 T1/2 T1/2 %T1/2
wtDFNA5- mutDFNA5- mutDFNA5-
Control Control wtDFNA5
BY4741 (HA-tagged) 19.83 ± 0.52 22.83 ± 0.26 31.38 ± 0.48 3.00 ± 0.24 11.54 ± 0.32 100.00 ± 1.42
BY4741 (EGFP-tagged) 20.30 ± 1.15 24.90 ± 2.61 35.88 ± 3.54 4.60 ± 1.27 15.58 ± 1.84 128.49 ± 8.60
aac1 Mitochondrial ADP/ATP
Carrier
31.30 ± 1.20 28.13 ± 5.36 31.08 ± 1.36 −3.18 ± 2.73 −0.22 ± 0.77 34.63 ± 11.17
aac3 Mitochondrial ADP/ATP
Carrier
24.70 ± 0.45 27.00 ± 0.82 29.40 ± 1.67 2.30 ± 0.45 4.70 ± 0.77 28.10 ± 3.37
aif1 Mitochondrial
Apoptosis-inducing factor
19.60 ± 0.22 23.13 ± 0.25 33.00 ± 0.82 3.53 ± 0.16 13.40 ± 0.42 115.61± 1.76
dnm1 Dynamin-related GTPase,
mitochondrial fission
20.20 ± 0.27 22.33 ± 1.61 31.50 ± 2.38 2.13 ± 0.94 11.30 ± 1.20 107.32 ± 6.07
fis1 Mitochondrial membrane
fission
26.70 ± 1.10 34.38 ± 1.80 48.67 ± 1.15 7.68 ± 1.02 21.97 ± 0.83 167.32 ± 5.26
mca1 Putative cysteine protease,
metacaspase
21.80 ± 0.27 24.30 ± 0.45 34.50 ± 2.27 2.50 ± 0.23 12.70 ± 1.14 119.41± 4.54
mdv1 Dmn1 adaptor protein,
mitochondrial fission
20.40 ± 1.34 24.38 ± 0.25 31.90 ± 2.01 3.98 ± 0.61 11.50 ± 1.08 88.10 ± 4.66
nma111 Omi1/HtrA2 Ortholog,
Serine protease
20.00 ± 0.00 23.67 ± 0.58 31.25 ± 2.22 3.67 ± 0.33 11.25 ± 1.11 88.78 ± 4.82
nuc1 Mitochondrial nuclease,
Endo G ortholog
22.38 ± 2.14 24.10 ± 0.55 33.67 ± 0.58 1.73 ± 1.10 11.29 ± 1.12 112.00 ± 6.54
por1 Mitochondrial porin, VDAC
homolog
20.50 ± 1.50 25.40 ± 0.65 40.00 ± 1.38 4.90 ± 0.91 19.50 ± 1.03 170.93± 5.53
por2 Putative mitochondrial porin,
VDAC homolog
21.20 ± 0.45 23.90 ± 0.42 31.30 ± 2.49 2.70 ± 0.27 10.10 ± 1.13 86.63 ± 4.31
rny1 Ribonuclease from yeast 20.90 ± 0.55 22.80 ± 0.57 33.90 ± 2.13 1.90 ± 0.35 13.00 ± 0.98 129.95 ± 3.87
snl1 Suppressor of nup116-C
lethal, Bag-1 homolog
18.60 ± 0.89 20.38 ± 0.25 28.00 ± 0.00 1.78 ± 0.42 9.40 ± 0.40 89.27 ± 2.33
tdh2 Triose-phosphate
dehydrogenase
20.13 ± 0.25 23.00 ± 0.50 31.00 ± 1.54 2.88 ± 0.31 10.88 ± 0.70 93.66 ± 3.07
tdh3 Triose-phosphate
dehydrogenase
22.00 ± 0.00 23.88 ± 0.25 35.50 ± 1.00 1.88 ± 0.13 13.50 ± 0.50 136.10 ± 2.13
tim18 Translocase of the inner
mitochondrial membrane
21.40 ± 0.42 25.50 ± 0.50 33.50 ± 0.58 4.10 ± 0.34 12.10 ± 0.34 93.66 ± 1.96
ymr074c Protein with homology to
human PDCD5
20.75 ± 0.50 23.70 ± 0.57 29.00 ± 3.32 2.95 ± 0.36 8.25 ± 1.50 62.05 ± 6.03
ysp Yeast suicide protein 20.00 ± 0.00 23.40 ± 1.39 34.10 ± 1.95 3.40 ± 0.62 14.10 ± 0.87 125.27 ± 4.18
T1/2: time to reach half maximal optical density (hours).
T1/2: difference in time to reach half maximal optical density (hours).
*Values are expressed as mean ± standard deviation.
these deposits were found at the periphery of the vacuole and
thus are likely to correspond to IPOD (Figure 2C). The small
foci formed by mutDFNA5-EGFP, neither co-localized with the
nucleus, nor with the vacuolar membrane but, interestingly,
seemed to partially overlap with DAPI-stained mitochondrial
DNA. This led us to visualize the mitochondrial network. The
strains were therefore co-transformed with a plasmid enabling
the expression of a mitochondrial red fluorescent marker protein,
Mito-RFP (Westermann and Neupert, 2000). Further analysis
revealed that, indeed, the small foci of mutDFNA5-EGFP often
co-localized with punctuated fragmented mitochondria and this
in contrast to the larger deposits of wtDFNA5-EGFP (Figure 2D).
MUTANT DFNA5 INDUCES CELL DEATH INDEPENDENTLY OF
CASPASE
Next, we systematically assessed the repercussion of wtDFNA5
and mutDFNA5 expression in strains harboring deletions of key
players of the programmed cell death machinery. We monitored
the expression of the HA-tagged DFNA5 proteins, compared the
growth profiles and measured the levels of ROS and cell death
during mid-exponential growth. One of the strains analysed
was the mutant lacking the yeast caspase, Mca1, which allowed
us to establish whether DFNA5-induced cell death involves the
previously described caspase-dependent or caspase-independent
processes (Madeo et al., 2009). As compared to the corresponding
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FIGURE 2 | Wild-type and mutant DFNA5 form inclusions in yeast. (A)
Fluorescence microscopic visualization and intracellular localization of
wtDFNA5-EGFP and mutDFNA5-EGFP fusion proteins in the BY4741
wild-type yeast strain sampled at the mid-exponential growth phase or in the
post-diauxic growth phase as indicated. Percentages refer to the number of
cells displaying a dispersed cytoplasmic localization or with inclusions. Cells
expressing only EGFP served as control. (B,C) Pictures of post-diauxic
wild-type cells with inclusions formed by wtDFNA5-EGFP or
mutDFNA5-EGFP and stained with DAPI (panel B) to visualize the nucleus or
with FM4-64 (panel C) to visualize the vacuolar membrane. (D) Pictures of
post-diauxic wild-type cells expressing wtDFNA5-EGFP or mutDFNA5-EGFP
and a mitochondrial red fluorescent marker protein, Mito-RFP.
wild-type strains, the mca1 strains displayed similar expres-
sion profiles of wtDFNA5 and mutDFNA5 (Figure 3A) and albeit
the mutant strains grew more slowly, they maintained similar
DFNA5-dependent growth defects as determined by calculat-
ing the T1/2 values (Table 3 and Figure 3B). In addition, the
deletion of MCA1 did not prevent accumulation of ROS upon
expression of mutDFNA5, nor did it prevent the mutDFNA5-
instigated induction of apoptotic and necrotic cell death mark-
ers (Figures 3C,D). Consistently, treatment of BY4741 wild-type
cells with the FITC-labeled pancaspase inhibitor z-VAD-FMK,
which binds to the active site of caspases in yeast (Madeo et al.,
2002), did not provide evidence for enhanced caspase activity
upon the expression of wtDFNA5 or mutDFNA5 (Figure 3E).
When combined, these observations suggest that mutDFNA5-
induced cell death occurs mainly independent of the caspase
Mca1. Likewise, we could exclude several of the other known play-
ers of the yeast apoptotic machinery to have amajor impact on the
DFNA5-dependent phenotypes. These included the mitochon-
drial cell death effector, Aif1, the mitochondrial endonuclease
G, Nuc1, the ortholog of the mammalian Omi/HtrA2 serine
protease, Nma111, as well as the yeast suicide protein, Ysp2
(Table 3 and data not shown).
MUTANT DFNA5 INDUCES CELL DEATH THROUGH
MITOCHONDRIAL FUNCTIONS
In contrast to the mutant strains mentioned above, we found
increased DFNA5-induced cytotoxicity in the strains lacking
either the mitochondrial outer membrane protein, Fis1 or the
voltage-dependent anion channel protein, Por1. The Fis1 protein
is involved in mitochondrial fission that attracts the dynamin-
related GTPase, Dnm1 through the adaptors Mdv1 and Caf4. The
complex then forms a contractile ring that promotes outer mem-
brane division. Interesting is that with the fis1 strains, both the
cultures expressing wtDFNA5 or mutDFNA5 displayed a compa-
rable lowermaximal optical density (Figure 4A). This is similar to
what we observed for cultures of wild-type cells transformed with
mutDFNA5 and it probably reflects the disturbance of mitochon-
drial dynamics. The role of Fis1 and mitochondrial fission in pro-
grammed cell death is still not fully clarified and seems to depend
on the type of the cell death stimulus (Braun and Westermann,
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FIGURE 3 | mutDFNA5-induced cell death does not involve the yeast
caspase. (A) Western blot analysis of protein extracts of mca1 cells
transformed with constructs allowing for the expression of C-terminally
HA-tagged wtDFNA5 or mutDFNA5 as indicated. Immunodetection was
performed using primary antibodies directed against the HA-tag or Adh2,
which was used as loading control. The black arrow indicates full-length
wtDFNA5 and the gray arrow full-length mutDFNA5. (B) Growth profiles of
mca1 cells expressing HA-tagged wtDFNA5 (dark gray squares) or
mutDFNA5 (black triangles) or transformed with an empty plasmid (light gray
circles). (C,D) Quantification of ROS accumulation using DHE staining
(panel C) or AV/PI positive cells (panel D) in mid-exponential cultures of
mca1 cells transformed with an empty plasmid (contr.) or with constructs
allowing for expression of C-terminally HA-tagged wtDFNA5 or mutDFNA5.
(E) Assessment of the caspase activity using FITC-tagged z-VAD-FMK in
BY4741 wild-type cells expressing C-terminally HA-tagged wtDFNA5 or
mutDFNA5 or transformed with an empty plasmid (contr.). Significances
were assayed using unpaired t-tests. For the AV/PI co-staining the following
significances were obtained when making the comparison with the control:
wtDFNA5: AV−/PI+ *; mutDFNA5: AV+/PI+ ***, AV−/PI+ ***. (* = p < 0.05;
** = p < 0.01; *** = p < 0.001).
2011). For instance, for ethanol-induced apoptosis, Fis1 was
shown to mediate mitochondrial fragmentation and cell death
independently of Dnm1 andMdv1 (Kitagaki et al., 2007), whereas
for acetic acid-induced apoptosis, Fis1 was reported to protect
cells by inhibition of Dnm1- and Mdv1-mediated mitochondrial
fission and cell death (Fannjiang et al., 2004). Concerning the
DFNA5-induced cell death, Fis1 obviously exerted a protective
function, but this appeared to be largely independent of Dnm1
and Mdv1 because neither the deletion of DNM1, nor the dele-
tion of MDV1 affected the DFNA5-mediated growth phenotype
(Table 3). As was to be expected, the levels of ROS were gen-
erally higher in the fis1 strains than in the wild-type strains
with a minor increment in case of wtDFNA5 expression, but a
clear augmentation in case ofmutDFNA5 expression (Figure 4B).
Likewise, the amount of dying cells in mid-exponential cultures
were in general higher in the fis1 strains as compared to the
wild-type strains, especially the number of early apoptotic cells,
and while there was no significant increase in the total number of
cells showing signs of cell death between the control and cultures
expressing wtDFNA5 or mutDFNA5, the latter two still showed a
trend toward enhanced late apoptosis and necrosis (Figure 4C).
Analysis of fis1 cells with combined expression of Mito-RFP
and EGFP-fusions showed that most cells contained fragmented
and aggregated mitochondria, which did not overlap with the
deposits formed by wtDFNA5-EGFP but clearly co-localized with
the foci of mutDFNA5-EGFP (Figure 4D). Similar as the loss
of Fis1, also the absence of the channel protein Por1 appeared
to sensitize cells for DFNA5-mediated cell death. However, with
Frontiers in Oncology | Molecular and Cellular Oncology July 2012 | Volume 2 | Article 77 | 8
Van Rossom et al. Yeast model for DFNA5 toxicity
FIGURE 4 | DFNA5 cytotoxicity is enhanced in cells lacking
mitochondrial functions. (A) Growth profiles of fis1 cells expressing
C-terminally HA-tagged wtDFNA5 (dark gray squares) or mutDFNA5 (black
triangles) or transformed with an empty plasmid (light gray circles). (B,C)
Quantification of ROS accumulation using DHE staining (panel B) or AV/PI
positive cells (panel C) in mid-exponential fis1 cultures without (contr.) or
with expression of HA-tagged wtDFNA5 or mutDFNA5. (D) Fluorescence
microscopy pictures of fis1 cells expressing EGFP or displaying inclusions
of wtDFNA5-EGFP or mutDFNA5-EGFP and co-transformed with Mito-RFP to
visualize mitochondria. (E) Growth profiles of por1 cells expressing
HA-tagged wtDFNA5 (dark gray squares) or mutDFNA5 (black triangles) or
transformed with an empty plasmid (light gray circles). Significances were
assayed using unpaired t-tests. For the AV/PI co-staining of the fis1 cultures
the following significant p-values were obtained when making the
comparison with the control and mutDFNA5: AV+/PI+ **. (* = p < 0.05;
** = p < 0.001).
this por1 deletion strain it was difficult to correctly assess
the repercussions on ROS accumulation or cell death due to
the very slow growth of the cells transformed with mutDFNA5
(Figure 4E).
In two other mitochondrial mutants, i.e., the aac1 and aac3
deletion strains (Figures 5A,B), the growth differences between
the control cultures and the cultures expressing wtDFNA5 or
mutDFNA5 were almost annihilated, indicative that the lack of
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FIGURE 5 | mutDFNA5 cytotoxicity depends on the mitochondrial
ADP/ATP carriers. (A,B) Growth profiles of (A) aac1 cells or (B) aac3
cells expressing C-terminally HA-tagged wtDFNA5 (dark gray squares) or
mutDFNA5 (black triangles) or transformed with an empty plasmid (light gray
circles). (C,D) Quantification of ROS accumulation using DHE staining
(panel C) or AV/PI positive cells (panel D) in mid-exponential (ME) and
post-diauxic (PD) phase in aac3 cultures without (contr.) or with expression
of HA-tagged wtDFNA5 or mutDFNA5. (E) Fluorescence microscopy pictures
of aac3 cells expressing EGFP or displaying inclusions of wtDFNA5-EGFP
or mutDFNA5-EGFP and co-transformed with Mito-RFP to visualize
mitochondria. (F) Western blot analysis of protein extracts of the aac1,
aac3, fis1, por1 mutant strains transformed with constructs allowing for
the expression of C-terminally HA-tagged wtDFNA5 or mutDFNA5 as
indicated. Immunodetection was performed using primary antibodies
directed against the HA-tag or Adh2, which was used as loading control.
Significances were assayed using unpaired t-tests. For the AV/PI co-staining
the following significances were obtained when compared to the control: for
wtDFNA5 in PD: AV+/PI+ *, AV−/PI+ *. (* = p < 0.05; *** = p < 0.001).
Aac1 or Aac3 abrogated the mutDFNA5-associated cytotoxicity.
AAC1 and AAC3 encode for two of the three ADP/ATP carriers of
the inner mitochondrial membrane. Previously reported studies
implicated these proteins as effectors of acetic acid-induced
apoptosis, a role which apparently does not depend on their
ADP/ATP translocase activity but rather on their impact on the
mitochondrial outer membrane permeabilization and mitochon-
drial degradation (Pereira et al., 2007, 2010). As documented
Frontiers in Oncology | Molecular and Cellular Oncology July 2012 | Volume 2 | Article 77 | 10
Van Rossom et al. Yeast model for DFNA5 toxicity
for the aac3 mutant, the deletion of the ADP/ATP carrier did
not prevent the accumulation of ROS during the post-diauxic
phase in cells expressing wtDFNA5 or mutDFNA5 (Figure 5C).
However, the lack of Aac3 clearly interfered with the appear-
ance of cell death markers. In the aac3 control cultures, the
levels of dying cells were markedly higher as compared to con-
trol culture of wild-type cells, which is consistent with the fact
that the aac3 mutant grows slower. The cultures with cells
expressing wtDFNA5 or mutDFNA5 still displayed altered ratios
between early or late apoptotic and necrotic cells, but the total
number of cells with signs of cell death did not alter in the dif-
ferent growth phases. Furthermore, the total number of dying
cells was comparable for the control culture and the culture of
cells expressing wtDFNA5 and it was consistently lower for the
culture of cells expressing mutDFNA5 (Figure 5D). Similar data
were obtained for the aac1 mutant (data not shown). These
observations confirm that mutDFNA5 requires the ADP/ATP car-
riers to instigate cytotoxicity and cell death. Furthermore, while
ROS production has been described as an event common to
most of the yeast apoptosis scenarios, our data demonstrate that
in the ADP/ATP carrier mutants the correlation between ROS
accumulation and viability does not hold. As such, our data
are completely in line with previously reported results obtained
with a triple aac1-3 mutant for acetic acid-induced apoptosis
(Pereira et al., 2007).
Analysis of aac3 cells co-transformed with Mito-RFP and
the EGFP-fusions revealed that these cells harbor a well devel-
oped mitochondrial tubular network. Even in cells expressing
mutDFNA5-EGFP such a tubular network was present, but there
were still punctuated mitochondria co-localizing with the foci of
the EGFP fusion (Figure 5E). This led us to conclude that the
absence of the ADP/ATP carriers did not prevent mutDFNA5 to
interfere with mitochondrial fission and fusion dynamics or the
clearance of fragmented mitochondria, which both are aspects
that remain to be studied in more detail.
Finally, it should be noted that we did not observe signifi-
cant differences in expression or degradation of the HA-tagged
wtDFNA5 or mutDFNA5 proteins between the wild-type strain
and the different mutant strains (Figure 5F). This indicates that
the observed changes in DFNA5-instigated cytotoxicity in the
mutant strains are related to their deleted functions and not to
alterations in DFNA5 expression.
DFNA5 TOXICITY IS CONFINED TO ITS FIRST GLOBULAR DOMAIN
We recently proposed that wtDFNA5 is composed of two globu-
lar domains, which are separated by a hinge region (Figure 6A).
In that study, we also demonstrated that the first domain induces
apoptotic cell death in transfected HEK293T cells, which led to
a model where the second domain can fold back to mask and
regulate the apoptotic activity of the first domain (Op de Beeck
et al., 2011b). Here, we expressed the two domains separately in
yeast. As shown, the expression of the first domain, designated
domain A and corresponding to the amino acid residues 1–256,
triggered a very pronounced growth defect that by far surpassed
the defect observed for mutDFNA5 (Figure 6B). Expression of
the second domain, referred to as domain B and corresponding
to residues 282–496, did not affect growth and the growth curve
FIGURE 6 | DFNA5 cytotoxicity is confined to its first globular domain.
(A) Schematic representation of wtDFNA5 with the two globular domains
connected by the hinge region and the indication of the mutants HCA-F2R
and HCA-A3R (boxed) in the first domain. (B) Growth profiles of BY4741
cells expressing the first (gray triangles) or the second (gray squares)
globular domain of wtDFNA5 or expressing point mutants in the first
globular domain, i.e., mutants HCA-F2R (open squares) or HCA-A3R (open
triangles). The dashed line is given as reference and depicts the growth of
BY4741 cells transformed with an empty plasmid. (C) Cell viability of
HEK293T cells transiently expressing the HCA-F2R and HCA-A3R mutants,
wtDFNA5 and mutDFNA5 as indicated. Significances were assayed using
One-Way ANOVA (*** = p < 0.001). Cells expressing EGFP served as
control (contr.).
almost perfectly overlapped with the one obtained for the empty
vector control.
DFNA5 belongs to the gasdermin protein family, named after
the founder protein GSDMA, which is involved in gastric can-
cer and also harbors pro-apoptotic activities (Saeki et al., 2007).
Sequence alignment of the different gasdermin family mem-
bers show a high degree of conservation, especially in the first
domain, which based on hydrophobic cluster analysis contains
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short α-helical folds interspaced by β-sheets (Op de Beeck et al.,
2011b). To document the importance of these structures for
the apoptotic-inducing activity of the domain, we used PCR-
based site directed mutagenesis and phenotypically tested two
of the mutants generated in domain A (Figure 6A). The first
mutant, designated HCA-F2R, contained the substitution of a
highly conserved hydrophobic phenylalanine into a basic argi-
nine, thereby disrupting the first α-helical fold. When expressed
in yeast, this mutant only triggered a small growth defect (T1/2:
3.33 h ± 0.93) and thus lost most of the apoptotic-inducing
activity (Figure 6B). In the second mutant, i.e., HCA-A3R, a non-
conserved alanine residue was changed into arginine. Although
this mutation also affected the first α-helical fold, its repercus-
sions on the apoptotic-inducing activity were less pronounced as
evidenced by the observation that the expression of this mutant in
yeast resulted in an intermediate growth defect (T1/2: 20.50 h±
5.96; Figure 6B).
Next to the experiments in yeast, we also assessed the cell
viability of human HEK293T cells transiently expressing the
generated DFNA5mutants. The expression of the HCA-A3R con-
struct led to a significant decrease of cell viability (mean viability:
38.28% ± 9.37), whereas expression of HCA-F2R did not (mean
viability: 78.60% ± 4.03), as it gave a similar cell viability as that
observed for cells transfected with an empty EGFP vector (mean
viability: 77.59% ± 5.58; Figure 6C). In fact, the cell viability of
cells expressing HCA-A3R is highly comparable to those express-
ing mutDFNA5, while cell viability of cells expressing HCA-F2R
is comparable to cells expressing wtDFNA5. As such, the results
obtained in HEK293T cells confirm those obtained in yeast.
DISCUSSION
In this study we analysed the repercussion of heterologous expres-
sion of human wtDFNA5 or mutDFNA5 in Saccharomyces cere-
visiae. Our data clearly demonstrate that mutDFNA5 causes a
significant growth defect, which is associated with an increased
number of late apoptotic and necrotic cells especially when
the culture entered the stationary phase, and this in contrast
to wtDFNA5. These findings confirm previous reported results
showing that mutDFNA5 induces apoptotic and necrotic cell
death when expressed in mammalian cells (Van Laer et al., 2004;
Op de Beeck et al., 2011b).
Detailed analysis of the expression of wtDFNA5 and
mutDFNA5 in the yeast system revealed that both proteins form
inclusions. For wtDFNA5, these inclusions most likely corre-
spond to IPOD as they are found at the periphery of the vacuole.
The IPOD is a protein quality control compartment where pro-
teins are deposited that presumably await autophagic clearance
(Bagola and Sommer, 2008; Kaganovich et al., 2008). This sug-
gests that wtDFNA5 is subjected to the normal cellular repertoire
of protein quality control and clearancemechanisms. MutDFNA5
seems to escape these quality control systems. It does not form
large IPOD-like deposits but rather smaller and more numerous
foci, which are less intense and occurring mostly in the vicin-
ity of the plasma membrane. Previous studies already suggested
an association of mutDFNA5 with the plasma membrane and/or
a membrane protein in mammalian cells, but the exact loca-
tion remained unclear (Van Laer et al., 2004; Op de Beeck et al.,
2011a). We now show that in yeast the foci formed bymutDFNA5
often co-localize with fragmented mitochondria, suggesting that
the mutant proteins may interact either with the mitochondrial
membrane or one of the mitochondrial membrane proteins,
which in turn may lead to mitochondrial impairment. The lat-
ter is further evidenced by the fact that mutDFNA5 is even more
toxic in the fis1 and por1 mutants, while it lost its specific
toxicity-inducing capacity inmutant strains lacking the ADP/ATP
carriers Aac1 and Aac3. It is remarkable that the same mitochon-
drial proteins have previously been identified as key players with
similar contributions for acetic acid-induced apoptosis in yeast
(Fannjiang et al., 2004; Pereira et al., 2007). This underscores that
mutDFNA5-instigated cytotoxicity and acetic acid-induced apop-
tosis build on common molecular mechanisms. Note that we did
not analyse the third ADP/ATP carrier Aac2 in our studies for the
simple reason that its deletion is lethal in the BY4741 background
(Chen, 2004).
The studies on acetic acid-induced apoptosis demonstrated a
protective function of Fis1 that relates to inhibition of Dnm1-
mediated mitochondrial fission and possible additional pro-
apoptotic Dnm1 functions (Fannjiang et al., 2004). Also for
mutDFNA5-induced cell death we found that Fis1 fulfils a pro-
tective role but this apparently does not involve Dnm1 or its
adaptor Mdv1. Indeed, our observation that neither the deletion
ofDNM1 nor ofMDV1 prevented mutDFNA5-induced cell death
excludes these fission proteins as downstream effectors. That Fis1
could have a specific function not shared by the other fission
factors Dnm1 and Mdv1 was already noted before in studies
dealing with ethanol-induced apoptosis. These studies suggested
that Fis1 has a specific role for the maintenance of mitochon-
drial fragmentation in response to ethanol (Kitagaki et al., 2007).
However, most recent studies revealed that fis1 mutants accu-
mulate secondary loss-of-function mutations in the WHI2 gene
(Cheng et al., 2008; Mendl et al., 2011), which encodes a protein
involved in cell cycle regulation (Radcliffe et al., 1997), the gen-
eral stress response, actin dynamics and Ras-cAMP-PKA signaling
(Kaida et al., 2002; Leadsham et al., 2009) as well as the selec-
tive degradation of dysfunctional mitochondria via autophagy,
a process known as mitophagy (Muller and Reichert, 2011). In
fact, the studies on cell death and mitophagy showed that the
enhanced sensitivity of the fis1 mutants toward cell death stim-
uli is solely due to the loss of the Whi2 function and not to the
lack of Fis1 (Cheng et al., 2008; Mendl et al., 2011). Also the fis1
mutant strain of the yeast deletion collection that was used in our
study appears to contain such a secondary loss-of-function muta-
tion in WHI2 (Cheng et al., 2008). Hence, it is feasible that the
enhanced mutDFNA5-instigated cytotoxicity in the fis1 mutant
strain relates to the WHI2 mutation and the consequent dimin-
ished stress resistance and lower rate of mitophagy, rather than to
a deficiency in mitochondrial fission. At least, it would explain the
observed accumulation of fragmented and aggregated mitochon-
dria co-localizing with the foci of mutDFNA5-EGFP in the fis1
mutant, and as such provide an additional confirmation that
mutDFNA5 triggers cell death through mitochondrial damage.
Another aspect of Fis1 is that the protein has similar biophysi-
cal properties as the mammalian Bcl2 and Bcl-xL and although
these anti-apoptotic proteins cannot replace the mitochondrial
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fission function of Fis1, they do substitute for Fis1 in cell viability
assays (Fannjiang et al., 2004). Bcl2 and Bcl-xL have important
roles as regulators of mitochondrial membrane permeabilization,
since they inhibit non-specific pore formation by the adenine
nucleotide translocator, ANT, the mammalian ortholog of the
Aac1/2/3 ADP/ATP carriers (Brenner et al., 2000; Belzacq et al.,
2003). Previous studies in yeast identified Fis1 as a potential reg-
ulator together with the mitochondrial permeability transition
pore components Aac1/3 and the VDAC protein Por1 for acetic
acid-induced cell death (Fannjiang et al., 2004; Pereira et al., 2007,
2010). Our data now demonstrate that mutDFNA5 cytotoxicity
is enhanced in the absence of Por1, while this toxicity is basi-
cally abrogated in the absence of Aac1 or Aac3. Whether this
means that mutDFNA5 directly targets the ADP/ATP carriers to
alter mitochondrial membrane permeability remains to be clari-
fied. In humans, mutations in the ANT1 gene are associated with
progressive external ophthalmoplegia (Sharer, 2005) and to our
knowledge there are no reports that link DFNA5 to this disorder
or, conversely, that link ANT1 to autosomal dominant deafness.
DFNA5 belongs to the gasdermin family. Although the mem-
bers of this family appear to have different molecular functions,
they share conserved structural features, such as the presence of
a globular domain in their N-terminal half (Saeki et al., 2007;
Tamura et al., 2007; Op de Beeck et al., 2011b). Intriguingly, this
domain harbors the DFNA5 capacity to induce cell death as con-
firmed in previous studies (Op de Beeck et al., 2011b) and ours. It
is not known whether this capacity to induce cell death is a com-
mon physiological property of all gasdermin family members, but
at least for one other member, i.e., GSDMA, this seems to be the
case since the protein was reported to induce apoptosis in a gas-
tric epithelial cell line (Saeki et al., 2007). The apoptosis-inducing
globular domain was proposed to be shielded in wtDFNA5 by a
second C-terminal regulatory domain. In mutDFNA5 a large part
of this regulatory domain is missing and therefore the apoptosis-
inducing domain is presumablymore exposed (Op de Beeck et al.,
2011a,b). Structurally, the apoptosis-inducing domain is com-
posed of short α-helical folds interspaced by β-sheets. Here, we
show that mutations disrupting the first α-helical fold strongly
reduce the cell death-inducing capacity of the N-terminal domain
in yeast and human HEK293T cells. This demonstrates the fea-
sibility to use the yeast system to further dissect the structural
requirements of DFNA5 associated with its apoptosis-inducing
property.
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